{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:06:54Z","timestamp":1789520814498,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroimmune Pharmacol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ample evidence has pointed to a close link between cardiovascular diseases (CVD) and depression. Inflammatory pathways including the high-mobility-group-box-1 protein, receptor-for-advanced-glycation-end-products and toll-like-receptor-4 (HMGB1\/RAGE\/TLR4) and nucleotide-binding domain (NOD)\u2013like receptor protein 3 (NLRP3) inflammasome pathways are thought to be crucial players in this link. Activation of these pathways ends by releasing of different inflammatory mediators involved in CVD and depression pathophysiology. In the brain, this inflammatory process enhanced indoleamine2,3-dioxygenase-1 (IDO-1) activation with subsequent alteration in kynurenine\/tryptophan levels causing depression. Based on the favorable anti-inflammatory effects of Alirocumab, the proprotein-convertase-subtilisin\/kexin-type-9 (PCSK9) inhibitor, used in different CVD, this study was designed to investigate its potential antidepressant effect. The behavioral and neurochemical effects of concomitant treatment of Alirocumab at doses of (4, 8 and 16\u00a0mg\/kg\/week subcutaneously) in Wistar rats exposed to chronic unpredictable mild stress (CUMS) for 6\u00a0weeks were assayed. Alirocumab prevented CUMS-induced depressive-like-behaviors exhibited in open-field and forced-swimming tests, and hypothalamus\u2013pituitary\u2013adrenal axis hyperactivity (adrenal gland weight and serum corticosterone). Alirocumab prevented CUMS-induced alteration in hippocampal kynurenine\/tryptophan levels and pro-inflammatory cytokines tumor-necrosis-factor-alpha, interleukin-1beta (IL-1\u03b2), IL-2 and IL-6. Western blot and PCR analysis showed that Alirocumab favorably modulated the HMGB1\/RAGE\/TLR4 axis, nuclear-factor-kappa-beta, NLRP3 inflammasome complex and IDO-1 in the hippocampus of CUMS rats. These effects were correlated to the level of PCSK9 expression. The behavioral and biochemical findings indicated the potential antidepressant effect of PCSK9 inhibition by Alirocumab.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s11481-023-10060-3","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T20:12:39Z","timestamp":1676319159000},"page":"195-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["PCSK9 Inhibition Reduces Depressive like Behavior in CUMS-Exposed Rats: Highlights on HMGB1\/RAGE\/TLR4 Pathway, NLRP3 Inflammasome Complex and IDO-1"],"prefix":"10.1007","volume":"18","author":[{"given":"Nevien","family":"Hendawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala H.","family":"Salaheldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2611-5300","authenticated-orcid":false,"given":"Sally A.","family":"Abuelezz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"10060_CR1","doi-asserted-by":"publisher","first-page":"119310","DOI":"10.1016\/j.lfs.2021.119310","volume":"273","author":"SA Abuelezz","year":"2021","unstructured":"Abuelezz SA, Hendawy N (2021) HMGB1\/RAGE\/TLR4 axis and glutamate as novel targets for PCSK9 inhibitor in high fat cholesterol diet induced cognitive impairment and amyloidosis. Life Sci 273:119310. https:\/\/doi.org\/10.1016\/j.lfs.2021.119310","journal-title":"Life Sci"},{"key":"10060_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11481-016-9712-7","volume":"12","author":"SA Abuelezz","year":"2017","unstructured":"Abuelezz SA, Hendawy N, Magdy Y (2017) targeting oxidative stress, cytokines and serotonin interactions via indoleamine 2, 3 dioxygenase by coenzyme Q10: role in suppressing depressive like behavior in rats. J Neuroimmune Pharmacol 12:277\u2013291. https:\/\/doi.org\/10.1007\/s11481-016-9712-7","journal-title":"J Neuroimmune Pharmacol"},{"key":"10060_CR3","doi-asserted-by":"publisher","first-page":"4126","DOI":"10.2174\/13816128113196660738","volume":"20","author":"G Anderson","year":"2014","unstructured":"Anderson G, Maes M (2014) Oxidative\/nitrosative stress and immunoinflammatory pathways in depression: treatment implications. Curr Pharm Des 20:4126\u20134161","journal-title":"Curr Pharm Des"},{"key":"10060_CR4","doi-asserted-by":"publisher","first-page":"e010838","DOI":"10.1161\/jaha.118.010838","volume":"8","author":"N Apaijai","year":"2019","unstructured":"Apaijai N, Moisescu DM, Palee S, Mcsweeney CM, Saiyasit N, Maneechote C, Boonnag C, Chattipakorn N, Chattipakorn SC (2019) Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia\/reperfusion injury through reduction of neuronal inflammation and amyloid b aggregation. J Am Heart Assoc 8:e010838. https:\/\/doi.org\/10.1161\/jaha.118.010838","journal-title":"J Am Heart Assoc"},{"key":"10060_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.nbd.2006.07.014","volume":"24","author":"CL Bellac","year":"2006","unstructured":"Bellac CL, Coimbra RS, Christen S, Leib SL (2006) Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. Neurobiol Dis 24:395\u2013402","journal-title":"Neurobiol Dis"},{"key":"10060_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.31887\/DCNS.2018.20.1\/mdehert","volume":"20","author":"M De Hert","year":"2018","unstructured":"De Hert M, Detraux J, Vancampfort D (2018) The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 20:31\u201339","journal-title":"Dialogues Clin Neurosci"},{"key":"10060_CR7","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.7150\/thno.45939","volume":"10","author":"Z Ding","year":"2020","unstructured":"Ding Z, Wang X, Liu S, Zhou S, Kore RA, Mu S, Deng X, Fan Y, Mehta JL (2020) NLRP3 inflammasome via IL-1 b regulates PCSK9 secretion. Theranostics 10:7100\u20137110. https:\/\/doi.org\/10.7150\/thno.45939","journal-title":"Theranostics"},{"key":"10060_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","volume":"46","author":"DJ Dwivedi","year":"2016","unstructured":"Dwivedi DJ, Grin PM, Khan M, Prat A, Zhou J, Fox-Robichaud AE, Seidah NG, Liaw PC (2016) Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis. Shock 46:672\u2013680","journal-title":"Shock"},{"key":"10060_CR9","unstructured":"EEC Directive of (1986) COUNCIL DIRECTIVE of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes (86\/609\/EEC)"},{"key":"10060_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MOL.0000000000000523","volume":"29","author":"TD Filippatos","year":"2018","unstructured":"Filippatos TD, Christopoulou EC, Elisaf MS (2018) Pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 inhibitors? Curr Opin Lipidol 29:333\u2013339","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"10060_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1474-4422(19)30034-1","volume":"18","author":"GBD 2016 Stroke Collaborators","year":"2019","unstructured":"GBD 2016 Stroke Collaborators (2019) Global, regional, and national burden of stroke, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):439\u2013458. https:\/\/doi.org\/10.1016\/S1474-4422(19)30034-1","journal-title":"Lancet Neurol"},{"key":"10060_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.biopsych.2007.04.020","volume":"62","author":"S Guo","year":"2007","unstructured":"Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B (2007) Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson\u2019s disease through inhibition of ROS-NO pathway. Biol Psychiatry 62:1353\u20131362","journal-title":"Biol Psychiatry"},{"key":"10060_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","volume":"58","author":"L Joseph","year":"2015","unstructured":"Joseph L, Robinson JG (2015) Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition and the future of lipid loweringtherapy. Prog Cardiovasc Dis 58:19\u201331","journal-title":"Prog Cardiovasc Dis"},{"key":"10060_CR14","doi-asserted-by":"publisher","unstructured":"Kotov SV, Isakova EV, and Sheregeshev VL (2020) Possibilities for correcting emotional and behavioral impairments in stroke patients during rehabilitation therapy. Neurosci Behav Physiol 50(2). https:\/\/doi.org\/10.1007\/s11055-019-00882-1 (February)","DOI":"10.1007\/s11055-019-00882-1"},{"issue":"9","key":"10060_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/kjm2.12225","volume":"36","author":"L Lei","year":"2020","unstructured":"Lei L, Li X, Yuan YJ, Chen ZL, He JH, Wu JH, Cai XS (2020) Inhibition of proprotein convertase subtilisin\/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing toll-like receptor 4\/nuclear factor-kappa B. Kaohsiung J Med Sci 36(9):705\u2013711. https:\/\/doi.org\/10.1002\/kjm2.12225","journal-title":"Kaohsiung J Med Sci"},{"key":"10060_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.neuroscience.2016.02.050","volume":"322","author":"Z Liu","year":"2016","unstructured":"Liu Z, Qi Y, Cheng Z, Zhu X, Fan C, Yu SY (2016) The effects of ginsenoside Rg1 on chronic stress induced depression-like behaviors, BDNF expression and the phosphorylation of PKA and CREB in rats. Neuroscience 322:358\u2013369. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.02.050","journal-title":"Neuroscience"},{"issue":"12","key":"10060_CR17","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/ijnp\/pyy087","volume":"21","author":"FW Lohoff","year":"2018","unstructured":"Lohoff FW (2018) Lipid-lowering drug effects beyond the cardiovascular system: relevance for neuropsychiatric disorders. Int J Neuropsychopharmacol 21(12):1076\u20131078. https:\/\/doi.org\/10.1093\/ijnp\/pyy087. (Advance Access Publication October 17, 2018 Commentary)","journal-title":"Int J Neuropsychopharmacol"},{"key":"10060_CR18","doi-asserted-by":"publisher","unstructured":"Macchi C, Ferri N, Sirtori CR, Corsini A, Banach M, Ruscica M (2021) Proprotein Convertase Subtilisin\/Kexin Type 9: A View beyond the Canonical Cholesterol-Lowering Impact. Am J Pathol 191(8):1385\u20131397. https:\/\/doi.org\/10.1016\/j.ajpath.2021.04.016. Epub 19 May 2021. PMID: 34019847","DOI":"10.1016\/j.ajpath.2021.04.016"},{"key":"10060_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12877-019-1177-0","volume":"19","author":"D Mohammad","year":"2019","unstructured":"Mohammad D, Herrmann N, Saleem M, Swartz RH, Oh PI, Bradley J, Chan P, Ellis C, Lanct\u00f4t KL (2019) Validity of a novel screen for cognitive impairment and neuropsychiatric symptoms in cardiac rehabilitation. BMC Geriatr 19:163. https:\/\/doi.org\/10.1186\/s12877-019-1177-0","journal-title":"BMC Geriatr"},{"key":"10060_CR20","doi-asserted-by":"publisher","unstructured":"Pesarico AP, Chagas PM, Nacher J (2021) Editorial: animal models of stress-current knowledge and potential directions. Front Behav Neurosci. https:\/\/doi.org\/10.3389\/fnbeh.2021.655214 (EDITORIAL article, 16 February)","DOI":"10.3389\/fnbeh.2021.655214"},{"key":"10060_CR21","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00018-018-2930-9","volume":"76","author":"A Raucci","year":"2019","unstructured":"Raucci A, Di Maggio S, Scavello F, D\u2019Ambrosio A, Bianchi ME, Capogrossi MC (2019) The Janus face of HMGB1 in heart disease: a necessary update. Cell Mol Life Sci 76:211\u2013229. https:\/\/doi.org\/10.1007\/s00018-018-2930-9","journal-title":"Cell Mol Life Sci"},{"key":"10060_CR22","first-page":"395","volume":"53","author":"GT Rezin","year":"2008","unstructured":"Rezin GT, CardosoMR G, Alves CL, Scaini G, Fraga DB, Riegel RE (2008) Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neuro Chem Int 53:395\u2013400","journal-title":"Neuro Chem Int"},{"key":"10060_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/MOL.0000000000000484","volume":"29","author":"NG Seidah","year":"2018","unstructured":"Seidah NG, Chr\u00e9tien M, Mbikay M (2018) The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation. Curr Opin Lipidol 29:144\u2013150","journal-title":"Curr Opin Lipidol"},{"key":"10060_CR24","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fphar.2015.00262","volume":"6","author":"B-Z Shao","year":"2015","unstructured":"Shao B-Z, Xu Z-Q, Han B-Z, Su D-F, Liu C (2015) NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol 6:262. https:\/\/doi.org\/10.3389\/fphar.2015.00262","journal-title":"Front Pharmacol"},{"key":"10060_CR25","first-page":"1","volume":"31","author":"JW Shin","year":"2010","unstructured":"Shin JW, Seol IC (2010) Interpretation of animal dose and human equivalent dose for drug development. J Korean Orient Med 31:1\u20137","journal-title":"J Korean Orient Med"},{"key":"10060_CR26","doi-asserted-by":"publisher","first-page":"Article ID 4293","DOI":"10.1155\/2020\/4293206","volume":"2020","author":"Y Tong","year":"2020","unstructured":"Tong Y, Wang Z, Cai Li, Lin L, Liu J, Cheng J (2020) NLRP3 inflammasome and its central role in the cardiovascular diseases. Oxidative Med Cell Longev 2020:Article ID 4293206. https:\/\/doi.org\/10.1155\/2020\/4293206. (8 pages)","journal-title":"Oxidative Med Cell Longev"},{"issue":"2","key":"10060_CR27","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5853\/jos.2018.00773","volume":"20","author":"G Tsivgoulis","year":"2018","unstructured":"Tsivgoulis G, Safouris A, Kim D, Alexandrovb A (2018) Recent advances in primary and secondary prevention of atherosclerotic stroke. J Stroke 20(2):145\u2013166","journal-title":"J Stroke"},{"key":"10060_CR28","doi-asserted-by":"crossref","unstructured":"Wahid A, Chen W, Wang X, Tang X (2021) High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. Biomed Pharmacother 139:111555","DOI":"10.1016\/j.biopha.2021.111555"},{"key":"10060_CR29","first-page":"359","volume":"20","author":"B Wang","year":"2019","unstructured":"Wang B, Lian YJ, Su WJ, Lu LL, Li JM, Jiang CL, Wang YX (2019) Fr-HMGB1 and ds-HMGB1 activate the kynurenine pathway via different mechanisms in association with depressive-like behavior. Mol Med Rep 20:359\u2013367","journal-title":"Mol Med Rep"},{"key":"10060_CR30","doi-asserted-by":"publisher","first-page":"Article ID 4572","DOI":"10.1155\/2020\/4572185","volume":"2020","author":"M Wang","year":"2020","unstructured":"Wang M, Yan S, Zhou Y, Xie P (2020) trans-cinnamaldehyde reverses depressive-like behaviors in chronic unpredictable mild stress rats by inhibiting NF-\u03baB\/NLRP3 inflammasome pathway. Evid Based Complement Alternat Med 2020:Article ID 4572185. https:\/\/doi.org\/10.1155\/2020\/4572185. (17 pages)","journal-title":"Evid Based Complement Alternat Med"},{"key":"10060_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s002130050456","volume":"134","author":"P Willner","year":"1997","unstructured":"Willner P (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134:319\u2013329","journal-title":"Psychopharmacology"},{"key":"10060_CR32","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1111\/bph.15261","volume":"177","author":"X Xu","year":"2020","unstructured":"Xu X, Piao HN, Aosai F, Zeng XY, Cheng JH, Cui YX, Li J, Ma J, Piao HR, Jin X, Piao LX (2020) Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1\/TLR4\/NF-\u039ab and TNF-\u03b1\/TNFR1\/NF-\u03baB pathways. Br J Pharmacol 177:5224\u20135245","journal-title":"Br J Pharmacol"},{"key":"10060_CR33","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.3390\/ijms22115903","volume":"22","author":"F Z\u00e1dor","year":"2021","unstructured":"Z\u00e1dor F, Joca S, Nagy-Gr\u00f3cz G, Dvor\u00e1csk\u00f3 S, Sz\u0171cs E, T\u00f6mb\u00f6ly C, Benyhe S, V\u00e9csei L (2021) Pro-inflammatory cytokines: potential links between the endocannabinoid system and the kynurenine pathway in depression. Int J Mol Sci 22:5903. https:\/\/doi.org\/10.3390\/ijms22115903","journal-title":"Int J Mol Sci"},{"key":"10060_CR34","doi-asserted-by":"publisher","first-page":"e100084","DOI":"10.1136\/gpsych-2019-100084","volume":"32","author":"H Zhang","year":"2019","unstructured":"Zhang H, Ding L, Shen T, Peng D (2019a) HMGB1 involved in stress-induced depression and its neuroinflammatory priming role: a systematic review. General Psychiatry 32:e100084. https:\/\/doi.org\/10.1136\/gpsych-2019-100084","journal-title":"General Psychiatry"},{"key":"10060_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.intimp.2018.12.012","volume":"67","author":"WY Zhang","year":"2019","unstructured":"Zhang WY, Guo YJ, Han WX, Yang MQ, Wenc LP, Wangd KV, Jiang P (2019b) b. Curcumin relieves depressive-like behaviors via inhibition of the NLRP3 inflammasome and kynurenine pathway in rats suffering from chronic unpredictable mild stress. Int Immunopharmacol 67:138\u2013144","journal-title":"Int Immunopharmacol"}],"container-title":["Journal of Neuroimmune Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-023-10060-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11481-023-10060-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11481-023-10060-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T19:06:18Z","timestamp":1694113578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11481-023-10060-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":35,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10060"],"URL":"https:\/\/doi.org\/10.1007\/s11481-023-10060-3","relation":{},"ISSN":["1557-1890","1557-1904"],"issn-type":[{"value":"1557-1890","type":"print"},{"value":"1557-1904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper and that they did not receive any fund.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Competing Interest"}}]}}